About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

DORA and LP in Alzheimer's Disease Biomarkers

NCT06274528·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Chloe Meehan, MA
CONTACT
314-273-0878 cmeehan@wustl.edu
Crirstina Toedebusch
CONTACT
314-747-0646 toedebuschc@wustl.edu

Lead

University of Minnesota

With

National Institutes of Health (NIH)
Eisai Inc.
National Institute on Aging (NIA)

The overall goal of this project is to conduct an early stage (phase II) clinical trial of a dual orexin receptor antagonist (DORA), lemborexant, in cognitively normal older adults with amyloid deposition to demonstrate the feasibility and potential biological effectiveness of lemborexant's target engagement with multiple blood plasma and cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers. Orexins (also called hypocretins) are wake-promoting neuropeptides and blockade of orexin with a DORA increases sleep. The scientific premise of this project is that increased or enhanced sleep over 6 months by treatment with lemborexant will decrease the ratio of phosphorylated tau-181/tau-181 (pT181/T181) in blood and the concentration of CSF and plasma AD biomarkers (amyloid-β (Aβ), tau and phosphorylated tau (p-tau)) as well as neurodegeneration, inflammatory and synaptic AD biomarkers such as neurofilament light chain (NfL) (a non-tau marker of neuronal degeneration), soluble triggering receptor expressed on myeloid cells 2 (sTREM2) (a marker for immune response/microglial function), and neuronal pentraxin-2 (NPTX2) a marker for synaptic function) compared to placebo in amyloid-positive cognitively normal older adults. In addition, the investigators will also determine lemborexant's safety, pharmacokinetics (PK), and pharmacodynamics (PD) in this population. This study will enhance trial design and methods by providing critical information about dosing, safety, and target engagement of lemborexant on CSF and blood AD biomarkers to power phase III secondary prevention trials using lemborexant.

Age

65–any

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Male or female.
Any race or ethnicity.
Participants must be age ≥ 65 years and able to sign informed consent.
Global Clinical Dementia Rating (CDR) 0.
Willing and able to undergo study procedures.

You may not be if

History or reported symptoms suggestive of restless legs syndrome, narcolepsy, or parasomnia.
STOP-Bang score \>6 for participants without PAP.
Untreated sleep apnea AHI\>15
Poorly treated sleep apnea due to noncompliance or an AHI ≥ 10.
\- PAP compliance is defined as ≥ 4 hours per night \>70% of the nights.
Plasma p-Tau217/np-Tau217% \<2.5
Stroke.
History of renal impairment
* Defined as older adult patients with markers of kidney damage or eGFR \< 45.0 ml/min/1.73m2.
* Normal Limits ≥ 45.0 mL/min/1.73m2
History of hepatic impairment
* AST and/or ALT ≥ 2X upper limit of normal (ULN).
* Normal Limits: AST 11-47 IU/L and ALT 6-53 IU/L
HIV/AIDS.
History of substance abuse or alcohol abuse in the preceding 6 months.
Regular alcohol consumption 3 or more days a week over the last 6 months. Regular alcohol consumption is defined as having more than 2 alcoholic beverages within 3 hours of bedtime. Participants that agree to reduce alcohol consumption during the study may not be excluded.
History of presence of any clinically significant medical condition, behavioral or psychiatric disorder, or surgical history based on medical record or participant report that could affect the safety of the participant or interfere with study assessments or in the judgement of the Principal-Investigator (PI) if participant is not a good candidate.
Has any medical condition that, in the PI's or study team investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data. Potential medical conditions that will be exclusionary at the PI's or study team investigator's discretion:
* Cardiovascular disease requiring medication except for controlled hypertension.
* Pulmonary disease.
* Type I diabetes.
* Neurologic or psychiatric disorder requiring medication.
* Untreated depression
* Tobacco use.
* Use of sedating medications.
* Use of medications that interact with lemborexant (if cannot be discontinued).
* Abnormal safety labs.
History of current suicidal ideations.
Inability to speak and understand English.
Currently pregnant or breast-feeding.
In the opinion of the PI, the participant should be excluded due to an abnormal physical examination.
Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment.
Must not participate in another drug or device study prior to the end of this study participation.
Contraindication to lumbar puncture (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery).

The record

StatusRecruiting

PhasePhase 2

Taking part201

StartedMar 2024

UpdatedJul 13, 2026

Conditions

Alzheimer Disease

Where1

Washington University in St. Louis, School of Medicine
St Louis, Missouri, United States